Preliminary report of a clinical trial supporting the sequential use of an attenuated E39 peptide (E39') to optimize the immunologic response to the FBP (E39+GM-CSF) vaccine. (4th November 2015) - Jackson, Doreen; Qiao, Na; Greene, Julia M; Hale, Diane; Berry, John; Trappey, Alfred; Vreeland, Timothy; Clifton, Guy; Ibrahim, Nuhad; Toms, Annie; Peoples, George E; Mittendorf, Elizabeth A